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Background: Indigenous peoples worldwide are experiencing elevated rates of type 2 diabetes and its
complications. To better understand the disproportionate burden of diabetic end stage renal disease (ESRD) among
Canadian First Nations people (FN), we examined prevalence, determinants, and co-morbidities of chronic kidney
disease (CKD) within this population.
Methods: The 2007 Canadian FN Diabetes Clinical Management and Epidemiologic (CIRCLE) study conducted a
cross-sectional national medical chart audit of 885 FN adults with type 2 diabetes to assess quality of diabetes care.
In this sub-study, participants were divided by estimated glomerular filtration rate (eGFR in ml/min/1.73 m2), as well
as by albuminuria level in those with eGFRs => 60. Those with eGFRs => 60 and negative albuminuria were
considered to have normal/near normal kidney function (non-CKD). Using univariate and logistic regression analysis,
they were compared with participants having eGFRs => 60 plus albuminuria (CKD-alb) and with participants
having eGFRs <60 (CKD-eGFR <60).
Results: While 84.5% of total CIRCLE participants had eGFRs => 60, almost 60% of the latter had CKD-alb. Of the
15.5% of total participants with CKD-eGFR <60, 80% had eGFRs 30–60 (Stage 3 CKD) but over 10% (1.6% of total
participants) had ESRD. Independent determinants of CKD-alb were male gender and increasing diabetes duration,
systolic BP, A1C and total cholesterol. These plus smoking rates also discriminated between FN with micro- and
macro-albuminuria. Independent determinants of CKD-eGFR <60 were increasing age at diabetes diagnosis,
diabetes duration, total cholesterol and systolic BP. However, participants with CKD-eGFR <60 also displayed a
decreasing mean age of diabetes diagnosis as eGFR declined. Micro-vascular co-morbidities were significantly
associated with CKD-alb but both micro- and macro-vascular co-morbidities were associated with CKD-eGFR <60.
Only 35-40% of participants with CKD used insulin.
Conclusions: High prevalences of CKD-alb and early CKD-eGFR <60 among diabetic FN were largely related to
modifiable and treatable risk factors. However, an earlier age of diabetes diagnosis and longer duration of diabetes
characterized those with ESRD. These findings suggest that a failure to meet current standards of diabetes care
interacting with an age-related survival benefit contribute to the disproportionate burden of ESRD among FN and
possibly other Indigenous peoples.
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Rates of diabetic end stage renal disease (ESRD) are dis-
proportionately elevated among Indigenous peoples world-
wide [1,2]. In Canada, the incidence of diabetic ESRD
remains three times higher among First Nations people
(FN) than others, although disparities have diminished
slightly since peaking in the early 1990s [3]. After adjusting
for substantially higher diabetes prevalence among FN
compared to non-FN [4], these disparities are character-
ized by two important observations. First, compared with
their non-FN counterparts, a greater proportion of dia-
betic FN have normal estimated glomerular filtration rates
(eGFRs) but a higher prevalence of albuminuria [5-8]. Sec-
ond, FN are younger at diabetes diagnosis than non-FN
and experience a longer duration between diabetes and
ESRD diagnoses [3]. These findings suggest that diabetic
FN are more prone to the initial development of chronic
kidney disease (CKD) and may be more likely to survive
long enough to develop ESRD [6,9].
Although the analysis of administrative [3,4,8] and other
large databases [10,11] has greatly enhanced our under-
standing of the differences between FN and non-FN in the
epidemiology of diabetes and ESRD, the possible genetic
and environmental factors that underlie the observations
summarized above remain unclear. Because the current in-
vestigation utilized detailed individual level information
gathered as part of the Canadian First Nations Diabetes
Clinical Management and Epidemiologic (CIRCLE) study
[12], we were able to conduct the first comprehensive
study of prevalence, determinants, treatment and co-
morbidities of chronic kidney disease within a broad sam-
ple of adult FN people with type 2 diabetes across Canada.
The results provide new insights into the development
and progression of diabetic renal disease within this popu-
lation which we hope can be translated into more effective
prevention/management initiatives.
Methods
Research Design, Ethics Approval and Participant
Selection
The methodology used in the CIRCLE study has been
previously described [12]. Briefly, we carried out a cross-
sectional medical chart audit of 2007 data for 885 FN
adults (18 years and older) with type 2 diabetes who
lived in 19 First Nations communities across seven pro-
vinces in Canada. FN are one of three diverse Indigen-
ous populations of Canada which also include Inuit and
Métis. The study was approved by the University of
Western Ontario, the University of Toronto and Health
Canada Research Ethics Boards as well as by each Band
Council and other University ethics review boards as
required. Community participation was confirmed by a
research agreement after community consultations were
held. The Ownership, Control, Access and Possession(OCAP) principles developed by the National Aboriginal
Health Organization [13] were used to guide the ethical
conduct of the study.
A registry of all adults with type 2 diabetes was devel-
oped in each community. Potential CIRCLE participants
were then randomly selected from each community’s
registry and sequentially contacted for consent until up
to 50 people had agreed to participate. For the final ana-
lyses, medical chart auditing was successfully carried out
by trained local research assistants on 885 of 950 poten-
tial study participants.
Data Collection and Definition of Chronic Kidney Disease
Sub-Groups
Charts were audited for participant characteristics, a
range of diabetes quality care indicators derived from
clinical practice guidelines (CPG) [14], pharmacologic
treatment and the presence of co-morbidities that are
defined and described in more detail elsewhere (12).
Audits were carried out in 2008/09 for the latest health-
care information available for 2007 which was based on
a mean of 8.7 visits per participant. If data was missing
for 2007, the most recent value prior to that year was
used. All information was de-identified and entered into
an Access database using study identification numbers.
CIRCLE participants were sub-divided into groups
based on their estimated glomerular filtration rates (eGFR)
and urinary excretion of albumin. Because test results
were obtained from medical chart records, methods for
measuring serum creatinine and urine parameters were
those being used by the particular province rather than
being carried out in one centralized laboratory. eGFRs
were calculated using an equation based on the original
Modification of Diet in Renal Disease Study Group
(MDRD) equation which uses age, sex, serum creatinine,
and black/white ethnicity [15]. Thus for males: eGFR=
186 x (serum creatinine x 0.0113)-1.154 x age (years)-0.203
and for females: eGFR= 186 x (serum creatinine x
0.0113)-1.154 x age (years)-0.203 x 0.742. For ethnicity, we
used the unadjusted (white ethnicity) parameter which
has been preliminarily validated in a North American In-
dian population [16]. Only those who had at least one
serum creatinine result during the study year were
included in this sub-study. When more than one result
was available, we utilized the lowest value to avoid results
possibly associated with acute renal impairment.
The eGFR sub-groups were based on chronic kidney dis-
ease (CKD) stages [17] using the Kidney Disease Outcomes
Quality Initiatives classification (eGFR => 90 ml/min
per 1.73 m2=no CKD and stage 1, 60–89.9 =no CKD
and stage 2, 30–59.9 = stage 3, 15–29.9= stage 4, <15=
stage 5). Those with an eGFR <15 who were not receiving
renal replacement therapy (stage 5a) were combined with
stage 4 because of small numbers, while people receiving
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Finally, because there are particular limitations to the
MDRD eGFR equation at eGFRs => 60ml/min/1.73m2
(see DISCUSSION), we presented both overall data for
those with eGFRs => 60ml/min/1.73m2 as well as sub-
group information for those with eGFRs => 90 and 60–
90ml/min. Those with an eGFR => 60 were further sub-
divided by the presence or absence of albuminuria [14].
Micro-albuminuria was defined as a 24h urine value 30–
300mg/day for both sexes, or a urine albumin: creatinine
ratio (ACR) of 2.0-20.0mg/mmol for males, or an ACR of
2.8-28mg/mmol for females. Macro-albuminuria was
defined as a 24h urine value >300mg/day for both sexes, an
ACR >20.0 mg/mmol for males or an ACR >28 mg/mmol
for females. Ten individuals without an available ACR rec-
ord were considered to have micro-albuminuria because of
a chart diagnosis by a physician.
Statistical Analyses
After determining the distribution of CIRCLE participants
by eGFR stage (all) and by albuminuria positivity (those
with eGFRs => 60ml/min), we defined three groups for fur-
ther comparisons. Those with normal or near-normal kid-
ney function (non-CKD) had eGFRs => 60ml/min/1.73m2
and negative albuminuria. CKD was defined on the basis of
positive albuminuria in those with eGFRs => 60ml/min/
1.73m2 (CKD-alb) or an eGFR <60ml/min/1.73m2 regard-
less of albuminuria (CKD-eGFR <60). All subsequent com-
parisons were between people with either CKD-alb or
CKD-eGFR <60 and those with non-CKD; we compared
overall groups as well as subgroups defined by eGFR stage.
The following parameters were compared between
groups and sub-groups: gender; mean age at audit and dia-
betes diagnosis, and duration of diabetes; mean body mass
index (BMI); proportion of smokers; mean systolic blood
pressure (sBP); mean diastolic blood pressure (dBP); mean
glycosylated haemoglobin (A1C), mean total cholesterol
(TC); mean low density lipoprotein cholesterol (LDL);
mean high density lipoprotein cholesterol (HDL); propor-
tions with micro-vascular and macro-vascular co-
morbidities (total and by organ system); and proportions
receiving treatment with insulin and/or agents that target
the renin/angiotensin/aldosterone system (RAAS).
Univariate analyses employed chi square tests to
compare proportions and two tailed t-tests to com-
pare means. We also used trend analysis to compare
selected parameters by level of albuminuria (negative,
micro-albuminuria, macro-albuminuria) in those with
eGFRs => 60ml/min. Finally, multivariate analysis was
carried out by entering potential determinants of
CKD-alb or CKD-eGFR <60 (versus non-CKD) into a
logistic regression model. Statistical tests were con-
ducted using PASW Statistics version 18.0 and
p <0.05 was used to determine significance. Oddsratios (OR) and 95% confidence intervals (CI) were
determined in multivariate analyses.
Results
Of 885 CIRCLE participants, 850 had at least one serum
creatinine measured during the audit year of 2007.
Table 1 shows the proportions of those individuals by
eGFR stage. Urine albumin measurement was carried
out in 685 of the 850 participants but the eGFR distribu-
tion of persons with and without a urine albumin test
was almost identical. A large majority of total study par-
ticipants (84.5%) had an eGFR ≥60 ml/min. Of the latter
who also had a urine albumin test (583), 242 (41.5%)
had negative albuminuria (non-CKD) and 341 (58.5%)
had albuminuria (CKD-alb). Only 132 (15.5%) of total
study participants had an eGFR <60 ml/min/1.73 m2
(CKD-eGFR <60) including 8 (0.9%) who were receiving
dialysis. People with CKD-alb, CKD-eGFR <60 and
non-CKD totalled 715 people and were the subjects of
further analyses. Their mean age at time of audit was
55.6 years, and 65.3% were female.
Table 2 - Characteristics and comparison of non-CKD
and CKD-alb participants: Despite only 34.7% of males in
the total study group, people with CKD-alb were more
likely to be male than those with non-CKD (39.0% versus
30.2% respectively; p = 0.017). CKD-alb participants also
had a significantly longer duration of diabetes (10.3 versus
7.8 years; p< 0.0001) despite being similar in age at time
of diabetes diagnosis. Most people were obese (mean BMI
33.8). There was not a significant difference in adiposity
between CKD-alb and non-CKD participants although
there was a trend for the former to have lower BMIs. Simi-
larly, smoking rates were high overall (38.7%) but did not
differ significantly by albuminuria positivity.
Mean sBP was higher among those with CKD-alb than
non-CKD (133.3 versus 128.7 mm Hg; p< 0.001) but
mean dBP was similar. Mean A1C was almost one per-
centage higher in those with CKD-alb compared to those
with non-CKD (8.68 versus 7.72; p< 0.0001), while the
mean TC was the only lipid value that was significantly
higher among those with CKD-alb. Microvascular but
not macrovascular complications were significant co-
morbidities associated with CKD-alb. Finally, almost 35%
of CKD-alb participants were receiving insulin therapy and
almost 80% were on RAAS agents. These proportions were
significantly higher than those for non-CKD.
With respect to participants having an eGFR =
> 60 ml/min, those with an eGFR => 90 were younger
at time of diabetes diagnosis, and had a shorter duration
of diabetes than those with an eGFR from 60 to <90 ml/min.
Those with a higher eGFR also had higher A1C values; the
worst A1C levels were in those with eGFRs => 90 ml/min/
1.73 m2 and positive albuminuria (8.95 versus 8.05 in those
with no albuminuria; p< 0.0001).
Table 1 Circle participants by eGFR* category and urine albumin testing
Participant Numbers Total eGFR =>90 eGFR 60 to <90 eGFR 30 to <60 eGFR 15 to <30 eGFR <15 (no RRT**) eGFR <15 (RRT)
Non/Stage 1 CKD Non/Stage 2 CKD Stage 3 CKD Stage 4 CKD Stage 5a CKD Stage 5b CKD
People with eGFR
(% total)
850 451 (53.1) 267 (31.4) 105 (12.4) 13 (1.5) 6 (0.7) 8 (0.9)
People with eGFR & Urine
Albumin Test (% total)
685 367 (53.5) 216 (31.5) 84 (12.3) 10 (1.5) 4 (0.6) 4 (0.6)
Normal Urine Albumin
(% in eGFR Stage)
274 147 (40.1) 95 (44.0) 30 (35.7) 1 (10) 1 (25) 0 (0)
Micro-albuminuria
(% in eGFR Stage)
278 159 (43.3) 88 (40.7) 29 (34.5) 2 (20) 0 (0) 0 (0)
Macro-albuminuria
(% in eGFR Stage)
133 61 (16.6) 33 (15.3) 25 (29.8) 7 (70) 3 (75) 4 (100)
Micro/Macro-albuminuria
(% in eGFR Stage)
411 220 (59.9) 121 (56.0) 54 (64.3) 9 (90) 3 (75) 4 (100)
People included in further
analyses (% total)***
715 367 (51.3) 216 (30.2) 105 (14.7) 13 (1.8) 6 (0.8) 8 (1.1)
*Estimated glomerular filtration rates in ml/min/1.73 m2 – categories correspond to Chronic Kidney Disease (CKD) Stages. Those with eGFRs => 60 and no
albuminuria are non-CKD. Stage 1 plus Stage 2 = CKD-alb. Stages 3-5b = CKD-eGFR <60.
**Renal replacement therapy.
***Those with eGFR => 60 and a urine albumin test plus those with eGFR <60 with or without urine albumin test (Numbers in bold.)
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eGFR ≤60 and comparison with non-CKD partici-
pants: There continued to be a female predominance
overall but 7 of 8 people on dialysis were male. While the
mean age at diabetes diagnosis for people with an eGFR 30
to <60 ml/min/1.73 m2 (stage 3 CKD) was almost 10 years
older than non-CKD participants (52.95 versus 43.62 years;
p< 0.0001), the mean age at diabetes diagnosis of people
with eGFRs <30 ml/min/1.73 m2 was younger (42.17 for
those in Stage 4/5a and 35.88 for those in Stage 5b). This
was associated with a longer duration of about 20 years
from diabetes diagnosis in the latter two groups compared
to 14.3 years for those with stage 3 CKD.
Participants with CKD-eGFR <60 were slightly less
obese and had significantly lower smoking rates than those
with non-CKD. Mean sBP was significantly higher but
mean dBP was significantly lower compared to non-CKD.
There were no overall differences in A1C or lipid values
between people with CKD-eGFR <60 and non-CKD; how-
ever, the mean A1C level was significantly lower among
those on dialysis (6.25 versus 7.72; p= 0.033). In contrast
to participants with CKD-alb, those with CKD-eGFR <60
not only experienced a higher frequency of microvascular
but also of macrovascular co-morbidities.
Table 3 shows the characteristics of CIRCLE participants
with eGFR => 60 ml/min/1.73 m2 by level of albuminuria
(none, micro-albuminuria, macro-albuminuria). There was
a progressive increase in the proportion of males with
increasing albuminuria from 30.2% of those with no
albuminuria to 50% of those with macro-albuminuria
(p=0.003). Those with macro-albuminuria were also sig-
nificantly younger at time of diabetes diagnosis (38.5 years
versus almost 44 years in other two groups; p = 0.002), andhad a longer duration of diabetes (11.5 years versus
9.9 years and 7.8 years for those with micro-albumiuria
and no albuminuria respectively; p< 0.0001). People with
macro-albuminuria were significantly less obese (mean
BMI 31.6 versus >34 in the two other groups; p = 0.001),
and were more likely to smoke (52.2% versus 36.7% and
42.2% of those with micro-albuminuria and no albumin-
uria respectively; p = 0.04).
People with any level of albuminuria had a significantly
higher mean sBP (>130 mm Hg) than those with non-
CKD (128.7 mm Hg) but mean dBP’s were similar and
normal (<80 mm Hg) in all groups. There was a progres-
sive and highly significant increase in mean A1C by in-
creasing amounts of albuminuria, from 7.72% in those
with no albuminuria to 8.34% and 9.58% in those with
micro- and macro-albuminuria respectively (<0.0001). TC
also increased progressively from 4.38 mmol/L in those
with non-CKD to 4.49 and 4.93 mmol/L in those with
micro- and macro-albuminuria respectively (<0.0001).
Participants with macro-albuminuria also had significantly
higher levels of LDL and HDL cholesterol.
The proportion of CIRCLE participants with eye dis-
ease and neuropathy increased progressively and signifi-
cantly by level of albuminuria from under 8% in those
with no albuminuria to over 18% in those with macro-
albuminuria. Finally, although use of both insulin and
RAAS agents increased significantly with degree of albu-
minuria, only 39.4% of those with macro-albuminuria
were on insulin while over 90% of that group were tak-
ing RAAS agents.
Table 4 shows the results of multivariate analyses com-
paring CKD-alb and CKD-eGFR <60 participants with
those having non-CKD. Using logistic regression, male
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NUMBER 715 147 220 . . . 95 121 . . . 242 341 . . . 105 . . . 19 . . . 8 . . . 132 . . .
% FEMALE 65.3 68.7 63.6 n/s 71.6 56.2 69.8 61.0 0.017 72.4 n/s 68.4 n/s 12.5 0.002 68.2 n/s
AGE AT AUDIT 55.6 47.6 49.4 n/s 59.6 61.3 n/s 52.3 53.6 n/s 68.1 0.000 62.7 0.001 56.0 n/s 66.6 0.000
age diagnosis 44.3 39.7 39.4 n/s 49.9 48.1 n/s 43.6 42.4 n/s 53.0 0.000 42.2 n/s 35.9 n/s 50.4 0.000
duration diabetes 10.4 7.1 9.3 0.001 8.8 12.3 0.001 7.8 10.3 0.000 14.3 0.000 20.1 0.000 19.1 0.000 15.4 0.000
BMI 33.8 35.6 33.4 n/s 34.8 33.7 n/s 34.7 33.5 n/s 33.3 n/s 33.6 n/s 27.5 0.004 32.9 0.033
% SMOKER 38.7 50 48.5 n/s 30.4 27.3 n/s 42.2 41.1 n/s 23 0.001 27.8 n/s 37.5 n/s 26.2 0.002
BLD PRESSURE
sBP (mm Hg) 132.2 128.2 132.3 0.016 129.4 135.1 0.015 128.7 133.3 0.001 135.6 0.002 137.5 0.018 139.3 n/s 136.1 0.000
dBP (mm Hg) 75.5 76.3 77.3 n/s 75.4 74.9 n/s 75.9 76.4 n/s 72.2 0.002 74.05 n/s 72.8 n/s 72.5 0.002
BLOOD TESTS
A1C (mean %) 8.14 8.05 8.95 0.000 7.18 8.19 0.000 7.72 8.68 0.000 7.57 n/s 7.65 n/s 6.25 0.033 7.5 n/s
TC (mM) 4.52 4.38 4.70 0.006 4.37 4.45 n/s 4.38 4.61 0.008 4.48 n/s 4.84 n/s 4.66 n/s 4.54 n/s
LDL (mM) 2.38 2.34 2.44 n/s 2.33 2.33 n/s 2.33 2.40 n/s 2.39 n/s 2.6 n/s 2.44 n/s 2.43 n/s
HDL (mM) 1.21 1.21 1.25 n/s 1.19 1.18 n/s 1.20 1.22 n/s 1.23 n/s 1.23 n/s 1.04 n/s 1.22 n/s
COMORBIDITIES
All Macrovasc (%) 21.1 11.6 10.5 n/s 23.2 25.6 n/s 16.1 15.8 n/s 38.1 0.000 68.4 0.000 62.50 0.005 43.9 0.000
% periph vasc 3.9 0.7 1.4 n/s 3.2 5.0 n/s 1.7 2.6 n/s 4.8 n/s 31.6 0.000 50.0 0.000 11.4 0.000
% cerebro vasc 5.3 2.7 2.7 n/s 4.2 5.8 n/s 3.3 3.8 n/s 12.4 0.002 15.8 0.037 12.5 n/s 12.9 0.001
% combined heart 16.1 9.5 7.3 n/s 17.9 19.8 n/s 12.8 11.7 n/s 29.5 0.000 52.6 0.000 37.5 n/s 33.3 0.000
All Microvasc (%) 22.4 11.6 23.2 0.003 11.6 25.6 0.007 11.6 24.0 0.000 32.4 0.000 47.4 0.000 87.5 0.000 37.9 0.000
% foot disease 4.6 2.0 5.0 n/s 0.0 2.5 n/s 1.2 4.1 0.034 8.6 0.002 21.1 0.001 37.5 0.000 12.1 0.000
% eye disease 13.8 6.1 13.6 0.015 9.5 15.7 n/s 7.4 14.4 0.006 20.0 0.001 21.1 0.063 85.5 0.000 24.2 0.000
% neuropathy 12.7 6.1 13.2 0.021 7.4 14.0 n/s 6.6 13.5 0.005 17.1 0.003 21.1 0.046 87.5 0.000 22.0 0.000
MEDICATIONS
% Insulin 30.1 18.4 33.2 0.001 21.1 38 0.005 19.4 34.9 0.000 30.5 0.018 57.9 0.000 75 0.001 37.1 0.000
% RAAS agents 75.2 63.3 76.8 0.004 73.7 85.1 0.028 67.4 79.8 0.001 81.9 0.004 63.2 n/s 62.5 n/s 78.0 0.019
* BMI-body mass index, sBP-systolic blood pressure, dBP-diastolic Blood pressure, A1C-glycosylated hemoglobin, TC-total cholesterol, LDL-LDL cholesterol, HDL-HDL cholesterol; periph vasc-peripheral vascular disease;
cerebro vasc-cerebral vascular disease; combined heart- coronary artery disease and/or left ventricle hypertrophy and/or congestive heart failure. RAAS agents- containing angiotensin converting enzyme inhibitors or
angiotensin receptor blockers.



















Table 3 Characteristics of Circle participants with eGFR =>60 by degree of albuminuria
PARAMETER* People With eGFR =>60 and Urine Albumin (UA) Test
Total With UA UA neg (non-CKD) Micro-albuminuria** Macro-albuminuria** p
NUMBER (%) 583 (100) 242 (41.5) 247 (42.4) 94 (16.1) . . .
% FEMALE 64.7 69.8 65.2 50.0 0.003
AGE AT AUDIT – mean (SD) 53.1 (13.8) 52.3 (13.6) 54.6 (14.0) 50.9 (13.5) 0.046
at diabetes diagnosis – mean (SD) 42.9 (13.1) 43.6 (12.8) 43.9 (132.1) 38.5 (13.2) 0.002
diabetes duration – mean (SD) 9.3 (6.7) 7.8 (5.9) 9.9 (7.0) 11.5 (7.2) 0.000
BODY MASS INDEX – mean (SD) 34.0 (6.8) 34.70 (6.4) 34.33 (7.4) 31.59 (5.7) 0.001
% SMOKER 41.6 42.2 36.7 52.2 0.04
BLOOD PRESSURE
sBP mm Hg – mean (SD) 131.4 (16.8) 128.7 (15.1) 133.5 (17.4) 132.7 (18.5) 0.004
dBP mm Hg – mean (SD) 76.2 (10.7) 75.9 (10.2) 77.0 (10.5) 75.11 (12.3) n/s
BLOOD TESTS
AIC % – mean (SD) 8.28 (2.26) 7.72 (1.92) 8.34 (2.21) 9.58 (2.64) 0.000
TC mM – mean (SD) 4.51 (1.04) 4.38 (0.93) 4.49 (1.01) 4.93 (1.24) 0.000
LDL mM – mean (SD) 2.37 (1.82) 2.33 (0.77) 2.31 (0.81) 2.65 (0.93) 0.003
HDL mM – mean (SD) 1.22 (0.30) 1.20 (0.29) 1.20 (0.30) 1.30 (0.33) 0.017
COMORBIDITIES
% eye disease 11.5 7.4 13 18.1 0.015
% neuropathy 10.6 6.6 11.7 18.1 0.007
MEDICATIONS
% Insulin 28.5 19.4 33.2 39.4 0.000
% RAAS agents 74.6 67.4 75.7 90.4 0.000
*sBP-systolic blood pressure, dBP-diastolic blood pressure, A1C-glycosylated hemoglobin, TC-total cholesterol, LDL-LDL cholesterol, HDL-HDL cholesterol, RAAS
agents- containing angiotensin converting enzyme inhibitors or angiotensin receptor blockers.
**Micro-albuminuria plus Macro-albuminuria. = CKD-alb.
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(OR 1.04 per year; 95% CI’s 1.01, 1.08), increasing sBP (OR
1.02 per mm Hg; 95% CI’s 1.003, 1.03), increasing A1C (OR
1.19 per 0.1%; 95% CI’s 1.07, 1.33) and increasing TC (OR
1.32 per 0.1 mM; 95% CI’s 1.06, 1.64) were all independent
determinants for CKD-alb. While increasing age at diabetesTable 4 Adjusted odds ratios (OR) for associations between m
VARIABLE People With eGFR ≥60
Albuminuria (CKD-alb) versus
OR 95% CI**
Gender (male versus female) 1.86 1.19, 2.90
Diabetes Diagnosis Age (per year ") 0.9 0.97, 1.01
Diabetes Duration (per year ") 1.04 1.01, 1.08
Body Mass Index (per 1 unit ") 0.99 0.96, 1.02
Smoker (yes versus no) 1.01 0.66, 1.55
Systolic BP (per 1 mmHg ") 1.02 1.003, 1.03
Diastolic BP (per 1 mmHg ") 0.99 0.97, 1.02
A1C (per 0.1% ") 1.19 1.07, 1.33
Total Cholesterol (per 0.1 mM ") 1.32 1.06, 1.64
*Chronic Kidney Disease = eGFR ≥60 with albuminuria (CKD-alb) or eGFR <60 with/
**CI-confidence interval.diagnosis (OR 1.06 per year; 95% CI’s 1.03, 1.09), diabetes
duration (OR 1.19 per year; 95% CI’s 1.13, 1.26) and in-
creasing TC (OR 1.47 per 0.1 mM; 95% CI’s 1.08, 2.01)
were also independent determinants for CKD-eGFR <60,
sBP almost achieved significance as well (OR 1.02 per mm
Hg; 95% CI’s 0.999, 1.04; p=0.059).odel variables and chronic kidney disease*
and
Non-CKD
People With eGFR <60 (CKD-eGFR <60)
versus Non-CKD
sig OR 95% CI sig
0.006 1.86 0.91, 3.78 0.088
0.366 1.06 1.03, 1.09 <0.0001
0.023 1.19 1.13, 1.26 <0.0001
0.450 1.00 1.00, 1.00 0.552
0.979 0.97 0.47, 1.97 0.923
0.019 1.02 0.999, 1.04 0.059
0.99 0.99 0.95, 1.02 0.424
0.002 1.00 0.82, 1.21 0.96
0.014 1.47 1.08, 2.01 0.015
without albuminuria (CKD-eGFR <60).
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While recent reports have examined the relationship be-
tween chronic kidney disease (CKD) and diabetes in
other North American indigenous populations [18-20],
this is the most comprehensive study of prevalence,
determinants and co-morbidities of chronic kidney dis-
ease (CKD) that has been carried out among adult First
Nations people (FN) with type 2 diabetes in Canada. It is
also the first to include a broad representation of FN
communities from across the country. We have con-
firmed that a large majority of diabetic FN have normal
or near normal eGFRs but experience high rates of albu-
minuria [5-8], and that those who develop ESRD are
characterized by a younger age at diabetes diagnosis and
a longer exposure to the metabolic consequences of dia-
betes [3,9]. What we now show more clearly than previ-
ously reported is that the initial development of CKD in
this population is strongly related to modifiable and
treatable risk factors despite possible genetic and pre-
natal precursors. Furthermore, the development of ESRD
appears dependent on factors contributing to long term
survival of a small minority rather than to rapid progres-
sion of CKD.
Almost 60% of diabetic FN with eGFRs => 60 ml/min/
1.73 m2 in our study had micro- or macro-albuminuria
(CKD-alb) and this was clearly associated with suboptimal
diabetes management. Thus, we not only demonstrated
for the first time in this population that increasing A1C,
sBP, and TC were all independent determinants of CKD-
alb but that progressive increases in A1C and TC also
discriminated between those with micro- and macro-
albuminuria, with the latter group having mean A1C’s
>9.5%. Additionally, over 50% of those with macro-
albuminuria were smokers, more than 10 percentage
points higher than those with micro-albuminuria or non-
CKD. It is thus concerning to note that smoking rates
were also very high among the youngest sub-group in our
study, those with eGFRs 90 and higher. Interestingly, in-
creasing BMI was not associated with CKD-alb and those
with macro-albuminuria had lower BMI’s than others. This
might be due to weight loss associated with very poor gly-
cemic control and/or, because of their inadequate usage,
lack of the weight gain often related to glucose lowering
drugs.
A longer duration of diabetes and male gender were
also independent determinants of albuminuria. The im-
pact of disease duration was expected but has not been
previously shown in this population. Similarly, while a
higher frequency of albuminuria has been reported
among male FN with diabetes [6], this is the first time
that male gender has been identified as an independent
determinant of albuminuria among FN. Those with
macro-albuminuria, which included the highest propor-
tion of males, also had the highest A1C, TC andsmoking rates. Therefore, it is likely that differences in
lifestyle and diabetes management rather than under-
lying biologic differences largely account for the impact
of gender on development of albuminuria.
This study also provides insights into why diabetic FN
experience a higher risk for ESRD. Although independent
determinants of an eGFR <60 ml/min/1.73 m2 included
increases in age at diabetes diagnosis, duration of diabetes,
sBP and TC, we found that the mean age at diabetes diag-
nosis actually decreased from 53.0 years for those with
Stage 3 CKD to 35.9 years for those with Stage 5b CKD.
Furthermore, there was a reversal in the female: male ratio
from predominantly females in Stage 3 to overwhelmingly
males in Stage 5b. These are consistent with Saskatchewan
findings [6] and are most obviously explained by an age-
related survival effect whereby those younger at diabetes
diagnosis were more likely to survive after reaching Stage
3 CKD. Unlike overall mortality rates among diabetic FN
which tend to be worse for males [21], our findings from
this and previous studies [3,6] suggest that mortality dur-
ing the late stages of diabetic CKD appears to be higher
for females. Importantly, we have now provided evidence
that differential mortality likely contributes to both
ethnicity-based disparities in development of diabetic
ESRD [6] as well as to ESRD risk within FN populations.
As we and others have reported [6,22], mean A1C
levels actually decreased with declining eGFRs and were
lowest (6.25%) in those requiring RRT. This observation
may be due to uremia-related appetite suppression and
nutritional problems as supported by a parallel decline
in BMI, or to a reduction in exogenous insulin require-
ments related to declining renal function. Since it has re-
cently been shown that A1C values <6.5% are associated
with increased mortality among those with diabetic CKD
[19], this may be a factor in the poor median survival of
both FN and non-FN with diabetic ESRD [3].
While only micro-vascular comorbidities were signifi-
cantly associated with CKD-alb, both micro- and macro-
vascular comorbidities were related to CKD-eGFR <60.
The first finding is presumably due to the impact of
poor glycemic control on the development and progres-
sion of micro-vascular complications [23,24]. The sec-
ond finding is also important because the association of
macro-vascular co-morbidities with worsening eGFR
relates to both the underlying pathophysiology of these
complications and the implications for those with eGFRs
<60 ml/min. Thus, increasing TC, sBP and diabetes dur-
ation were all independent determinants of CKD-eGFR
<60, but are also known risk factors for macro-vascular
complications and death in those with diabetes [25,26].
Furthermore, impaired renal function also contributes to
the development of macro-vascular complications and
death [27,28]. Accordingly, our findings not only provide
a plausible explanation for mechanisms contributing
Dyck et al. BMC Nephrology 2012, 13:57 Page 8 of 10
http://www.biomedcentral.com/1471-2369/13/57to the development of CKD-eGFR <60 and its co-
morbidities, but also for the attendant increase in mor-
tality rates. Combined with the higher AIC levels that
we identified in those with earlier stages of CKD and
that have also been shown to be independently asso-
ciated with death in those with CKD [22], it is not sur-
prising that only a select minority of people with
diabetes live long enough to develop ESRD and that this
survivorship particularly favours those with a younger
age of diabetes onset.
Although people with CKD-alb and CKD-eGFR <60
were more likely to be on insulin and RAAS agents than
people with non-CKD, only the 80% on RAAS agents
approached Canadian Diabetes Association CPG guide-
lines recommending their use in those with CKD [14].
In contrast, only about 1/3 of FN with CKD were on in-
sulin – in the context of a mean A1C >8% for the total
study population and over 9.5% in those with macro-
albuminuria, these results indicate a critical need for
improvements in glycemia management. This is particu-
larly concerning when guidelines recommend insulin
therapy in those with A1Cs consistently >9% [14] and
when we have previously shown that diabetic FN are less
likely than their non-FN counterparts to achieve a target
A1C of 7% [29]. Finally, while we did not analyze the
use of lipid lowering agents in this sub-study, over 70%
of CIRCLE participants with an LDL >2.5% were receiv-
ing pharmacologic treatment. As we have noted previ-
ously [29], LDL values tend to be closer to target than
other diabetes quality care indicators among FN and
may not adequately reflect dyslipidemia in this popula-
tion. Instead, TC was an independent determinant of
both CKD-alb and CKD-eGFR <60.
Strengths of this study included its national scope,
randomized approach to participant selection, ability
to only include those with type 2 diabetes and use
of detailed individual level information. Limitations
included the use of opportunistic rather than random
sampling of FN communities across Canada. Thus, study
results do not necessarily represent the findings of all
FN people with diabetes in Canada. For example, we
observed a smaller proportion of CIRCLE participants
requiring RRT compared to their Saskatchewan FN
counterparts [6], possibly because of difficulty contacting
such individuals who frequently travel to or have relo-
cated to larger centers where dialysis facilities are avail-
able. Second, we were unable to identify CKD with
causes other than diabetes and did not have complete
data with respect to urine albumin testing. Third, in
some cases, a diagnosis of CKD-alb or CKD-eGFR <60
may have been made on the basis of a single urine albu-
min or serum creatinine test result and we can not rule
out the possibility that some abnormal results were due
to acute rather than chronic renal problems. Fourth,although few cases of albuminuria were based on 24
hour urine collections, over- or under- collection of
urine could have increased or decreased urine albumin
values respectively. Fifth, there are limitations to the
MDRD eGFR equation particularly at eGFRs => 60 ml/
min/1.73 m2 [30-32]. Accordingly, we have presented
both overall data for those with eGFRs => 60 ml/min/
1.73 m2 as well as sub-group information for those with
eGFRs => 90 and 60–90 ml/min. Finally, our cross-
sectional design did not allow the longitudinal follow up
of people as they transitioned from diabetes diagnosis
through the CKD stages. Importantly, this did not per-
mit us to determine mortality rates by diabetes duration,
eGFR and presence of albuminuria. The latter informa-
tion would have allowed us to further clarify the impact
of differential mortality related to the competing risks of
ESRD and death. In addition, the cross-sectional design
prevents us from making causal inferences and the use
of the terms “determinant” and “co-morbidity” is not
intended to imply that our findings have established a
cause-effect relationship.
Conclusions
Our results demonstrate that, despite the role of genetic
[33,34] and pre-natal factors [35] in the development
of diabetic kidney disease among Indigenous North
Americans, the development of albuminuria was more
immediately related to quality of diabetes care and other
modifiable risk factors such as smoking. Failure to
achieve or even approach CPG targets for glycemic, sys-
tolic blood pressure and possibly cholesterol control
clearly discriminated between those with and without al-
buminuria and was related to obvious deficiencies in
pharmacologic and lifestyle interventions. Why a small
proportion of those with early diabetic nephropathy pro-
gressed to eGFRs <60 ml/min/1.73 m2 also appeared
related to quality of diabetes care, but increasing age and
duration of diabetes also emerged as dominant factors.
Of particular importance in explaining the development
of diabetic ESRD, those with this devastating complica-
tion were almost 20 years younger at age of diabetes
diagnosis than those with Stage 3 CKD. The most plaus-
ible explanation for this observation was an age-related
survival benefit that allowed those with an earlier age of
diabetes onset to live long enough to develop ESRD.
This requires confirmation using longitudinal studies
that analyze the competing risks of ESRD and death
from the age of diabetes diagnosis. Nonetheless, the
overall message is clear. Rate disparities in diabetic
ESRD and earlier CKD Stages both within FN popula-
tions and between FN and others are potentially remedi-
able through early diagnosis of diabetes, smoking
cessation and by meeting established CPG targets for
glycemic, blood pressure and cholesterol control. Finally,
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ties and health care systems to promote healthy lifestyles
and develop effective primary prevention initiatives
[36,37]. It is possible that even delaying the onset of dia-
betes among FN could substantially reduce the incidence
of ESRD.
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